ERBB2 and breast carcinoma: Taken together, our findings provide a more complete picture of the scope of anti-cancer effects induced by the Cx43-targeted agent, aCT1, painting a picture of how to move forward with implementing a strategy for the use of this agent for HER2+ breast cancers, and perhaps other human cancers.